FDA D.I.S.C.O. Burst Edition: FDA approval of Lynparza (olaparib), with abiraterone and prednisone, for BRCA-mutated metastatic castration-resistant prostate cancer
0:00
3:30
Listen to a soundcast of the May 31, 2023, FDA approval of Lynparza (olaparib), with abiraterone and prednisone, for BRCA-mutated metastatic castration-resistant prostate cancer.”
Altri episodi di "FDA Drug Information Soundcast in Clinical Oncology (D.I.S.C.O.)"
Non perdere nemmeno un episodio di “FDA Drug Information Soundcast in Clinical Oncology (D.I.S.C.O.)”. Iscriviti all'app gratuita GetPodcast.